At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.
Patent # | Description |
---|---|
2017/0327581 |
Anti-Leukocyte Adhesion for the Mitigation of Potential Adverse Events
Caused by CD3-Specific Binding Domains The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a... |
2017/0327580 |
BISPECIFIC ANTIBODIES AGAINST CD3 EPSILON AND BCMA FOR USE IN TREATMENT OF
DISEASES The disclosure relates to bispecific antibodies against CD3c and BCMA for use in the treatment of diseases. The disclosure provides methods of determining the... |
2017/0327579 |
BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA A bispecific antibody specifically binding to the extracellular domain of human BCMA and human CD3.epsilon., characterized in comprising a common antibody... |
2017/0327578 |
ANTI-CEACAM1 RECOMBINANT ANTIBODIES FOR CANCER THERAPY Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their... |
2017/0327577 |
METHODS OF CONSTRUCTING AMINO TERMINAL IMMUNOGLOBULIN FUSION PROTEINS AND
COMPOSITIONS THEREOF Disclosed herein are immunoglobulin fusion proteins comprising a first immunoglobulin region attached to a therapeutic peptide at the amino terminus of the... |
2017/0327576 |
ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF The invention relates to an antigen binding site for binding to a P2X.sub.7 receptor, the antigen binding site being defined by general formula 1:... |
2017/0327575 |
Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using... |
2017/0327574 |
METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2... |
2017/0327573 |
Composition to induce bone marrow stem cell mobilization A pharmaceutical composition to induce bone marrow stem cell mobilization from the bone marrow to peripheral blood in patients suffering from pathological... |
2017/0327572 |
TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
BY ANTAGONISM OF THE IL-20R The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In... |
2017/0327571 |
ANTI-HUMAN IL-17 MONOCLONAL ANTIBODIES AND USE THEREOF The present application discloses a novel anti-human IL-17 monoclonal antibody obtained by phage antibody library screening and genetic engineering, or a... |
2017/0327570 |
ANTI-TNF-alpha FULLY HUMAN MONOCLONAL ANTIBODIES WITH LOW IMMUNOGENICITY
AND APPLICATION THEREOF Disclosed herein are low immunogenic human anti-TNF-.alpha. antibodies which can inhibit the apopotosis of cells induced by TNF-.alpha.. The invented low... |
2017/0327569 |
Novel Angiopoietin 2, VEGF Dual Antagonists The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF... |
2017/0327567 |
COMBINATION OF ANTI-PD-1 ANTIBODIES AND RADIATION TO TREAT CANCER The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., solid tumors). The methods of the present... |
2017/0327566 |
ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE The invention provides anti-human alpha-synuclein antibodies and methods of using the same. |
2017/0327565 |
CROSS-PROTECTIVE PATHOGEN PROTECTION, METHODS AND COMPOSITIONS THEREOF The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising... |
2017/0327564 |
COMPOSITIONS AND METHODS FOR TREATMENT IN BROAD-SPECTRUM, UNDIFFERENTIATED
OR MIXED CLINICAL APPLICATIONS The disclosure provides improved compositions and methods for passive immunization. In embodiments, a composition comprising a synergistic combination of... |
2017/0327563 |
Methods for Treating HIV-Associated Enteropathy Symptoms With
Immunoglobulin/Protein Isolate The present invention provides a method for treating human immunodeficiency virus (HIV)-associated enteropathy in subjects who have been on antiretroviral... |
2017/0327562 |
DESIGNER COLLAGENS AND USE THEREOF The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound... |
2017/0327561 |
Anti-Angiogenic Properties of Collagen V Derived Fragments The present invention relates to a peptide comprising an amino acid sequence at least 85% identical to the amino acid sequence as shown in SEQ ID NO. 1,... |
2017/0327560 |
GDF15 FUSION PROTEINS AND USES THEREOF Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion... |
2017/0327559 |
VIRAL INACTIVATION USING IMPROVED SOLVENT-DETERGENT METHOD The present specification discloses methods of inactivating a lipid-coat containing virus and proteins essentially free of a lipid-coat containing virus... |
2017/0327558 |
MAMMALIAN CELL CULTURE PROCESSES FOR PROTEIN PRODUCTION The present invention describes methods and processes for the production of proteins by animal cell or mammalian cell culture. In one aspect, the methods... |
2017/0327557 |
Efficient delivery of therapeutic molecules to cells of the inner ear Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by... |
2017/0327556 |
CARTILAGE-BINDING FUSION PROTEINS Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second... |
2017/0327555 |
MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT
OF AUTOIMMUNE DISEASES This invention provides for a fusion protein between an IL2.alpha..beta..gamma. Selective Agonist protein (IL2 Selective Agonist) and a IgG Fe protein. The IL2... |
2017/0327554 |
CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS The present invention provides a fusion protein, comprising a chemokine polypeptide, which is a chemokine or a receptor binding domain thereof; and a cytokine... |
2017/0327553 |
COMPOSITIONS AND METHODS FOR LONG ACTING PROTEINS The present invention provides peptide tags that can be linked to a therapeutic molecule in order to decrease the clearance of the therapeutic molecule from... |
2017/0327552 |
PEPTIDES AND COMPOSITIONS FOR TREATMENT OF JOINT DAMAGE The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions... |
2017/0327551 |
METHODS OF USING COMPOSITIONS COMPRISING FUSION VARIANTS OF FGF19
POLYPEPTIDES FOR REDUCING GLUCOSE LEVELS IN A... The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of... |
2017/0327550 |
NBP158 AND USES THEREOF This invention provides nucleic acid molecules encoding the N-terminal 158 amino acids of secreted human Fibroblast Growth Factor Binding Protein 3 (NBP158),... |
2017/0327549 |
Adenylation Enzyme Inhibitors The present invention concerns compounds that are capable of covalently entrapping adenylating enzymes. The present invention is essentially based on the... |
2017/0327548 |
Charged Nutritive Fragments, Proteins and Methods Charged nutritive proteins provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the... |
2017/0327547 |
Novel Chimeric Insecticidal Proteins Toxic or Inhibitory to Lepidopteran
Pests Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide... |
2017/0327546 |
Novel Insecticidal Proteins and Methods for Their Use Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal... |
2017/0327545 |
Modified Kappa Light Chain-Binding Polypeptides A kappa light chain-binding polypeptide comprising or consisting essentially of one or more binding domains of Peptostreptococcus Protein L, each of said... |
2017/0327544 |
RECOMBINANT VIRAL VECTORS The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The... |
2017/0327543 |
POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES The present invention relates to the field of vaccines. In particular, the present invention provides compositions and methods relating to virus-like particle... |
2017/0327542 |
TEICOPLANIN ANALOGS AND USES THEREOF Described herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present... |
2017/0327541 |
METHODS FOR SYNTHESIZING alpha4 7 PEPTIDE ANTAGONISTS The present invention provides methods of making .alpha.4.beta.7 peptide monmer and dimer antagonists. Methods of the present invention include solid phase and... |
2017/0327540 |
METHOD FOR ACYLATING A CYCLIC PEPTIDE The present invention relates to a process for acylating cyclic peptides bearing an amino group and to the application of said process in the preparation of... |
2017/0327539 |
Peptide and Complex of Same, Scaffold for Tissue Repair and Surface
Treatment Method for Same, and Surface... A peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a... |
2017/0327538 |
Peptide Inhibitors of Sodium Channels The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium... |
2017/0327537 |
BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations. The compounds described herein include... |
2017/0327536 |
NEUROTOXIC TARGET FOR AMYLOSPHEROID, METHOD AND MATERIAL FOR REDUCING THE
NEUROTOXICITY OF AMYLOSPHEROID, AND... In one or a plurality of embodiments, there is provided a target molecule of amylospheroid, which is expressed in mature neurons and to which the amylospheroid... |
2017/0327535 |
AFFINITY SEPARATION MATRIX FOR PURIFYING PROTEIN CONTAINING IMMUNOGLOBULIN
K CHAIN VARIABLE REGION An affinity separation matrix includes a water-insoluble base material; and a ligand that is immobilized on the water-insoluble base material, wherein the... |
2017/0327534 |
SEPARATION MATRIX The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands... |
2017/0327533 |
METHOD FOR SPECIFIC CLEAVAGE OF C Alpha-C BOND AND SIDE CHAIN OF PROTEIN
AND PEPTIDE, AND METHOD FOR... The present invention provides a method for specifically cleaving a C.alpha.-C bond of a peptide backbone and/or a side chain of a protein and a peptide, and a... |
2017/0327532 |
METHODS, COMPOSITIONS, AND KITS USING HETEROGENEOUS CATALYSTS Described herein are methods, compositions and kits utilizing heterogeneous metal catalysts for the preparation of cycloaddition compounds, such as triazoles... |
2017/0327531 |
6.ALPHA.-ALKYL-6,7-DIONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF
STEROIDAL FXR MODULATORS The invention relates to compounds of formula (I), wherein R.sup.1, R.sup.2, Y, R.sup.4 and R.sup.5b are as defined herein. The compounds are intermediates in... |